ReviewProgress in retinal and eye research2026
Clinical histopathology and pathogenesis of macular telangiectasia type 2.
Review in Progress in retinal and eye research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Prevalence and Visual Acuity Characteristics of Patients with Macular Telangiectasia.Ophthalmology and therapy · 2026Article
- Macular telangiectasia type 2: An update.The Journal of international medical research · 2026Review
- Longitudinal spatial correlation of retinal sensitivity and structural changes in macular telangiectasia type 2.International journal of retina and vitreous · 2026Article
- Is Macular Telangiectasia Type 2 Associated with Hearing Loss and Cochlear Dysfunction? A Prospective Case-Control Study.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Macular telangiectasia type 2 (MacTel) is a rare neurodegenerative retinal disease defined by a unique combination of reduced macular pigment, a characteristic angiographic pattern, and a localized clinical presentation. The condition typically affects the temporal perifovea and leads to progressive visual impairment. No definitive treatment exists. Current management is limited to intravitreal anti-vascular endothelial growth factor (VEGF) injections for end-stage neovascular complications and the recently approved Encelto implant (Neurotech Pharmaceuticals, Inc.), which delivers ciliary neurotrophic factor (CNTF) for neuroprotection. To clarify the still enigmatic pathophysiology of MacTel, we conducted a comprehensive review of all human histopathology reports published in English through December 31, 2024. Findings were systematically evaluated with respect to tissue processing techniques, postmortem fixation times, disease stage at last recorded ophthalmologic evaluation, diagnostic certainty, inclusion of control specimens, and the anatomic origin of analyzed retinal sections. This approach aimed to identify histopathologic features most likely to represent core disease mechanisms. Each of the features identified as most likely to be pathophysiologically relevant was independently assessed for clinical and histopathologic specificity. These features were then further interpreted in the context of genetic, metabolic, and anatomic associations reported in the literature. Donor demographics, coexisting ocular conditions, and systemic comorbidities were also reviewed to support the development of an integrative hypothesis for MacTel pathogenesis. Drawing on this synthesis, we propose a histopathology-informed model of disease pathophysiology and outline a provisional timeline for the contribution of key factors to clinical expression. We also review current neuroprotective strategies and provide targeted recommendations for future therapeutic development and histopathologic research. The conceptual framework developed in this work -grounded in rigorous analysis of the most consistent and methodologically validated histopathologic findings, and interpretation of their mechanistic context- may serve as a model for deciphering rare retinal diseases and for generating focused, hypothesis-driven questions to guide future investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.